

# Papua New Guinea

Population 2018

8.6 million

Estimates of TB burden <sup>o</sup> , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	37 (30–45)	432 (352–521)
HIV-positive TB incidence	2.7 (2.2–3.3)	32 (26–38)
MDR/RR-TB incidence <sup>oo</sup>	2 (1.2–2.9)	23 (14–33)
HIV-negative TB mortality	4.5 (3–6.2)	52 (35–72)
HIV-positive TB mortality	0.25 (0.1–0.45)	2.8 (1.2–5.2)

Estimated proportion of TB cases with MDR/RR-TB, 2018	
New cases	3.4% (1.7–5)
Previously treated cases	26% (15–36)

TB case notifications, 2018	
Total new and relapse	27 887
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	52%
- % pulmonary	56%
- % bacteriologically confirmed <sup>ooo</sup>	30%
- % children aged 0–14 years	24%
- % women	36%
- % men	40%
Total cases notified	29 364

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2018	75% (62–92)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	13% (8–18)

TB/HIV care in new and relapse TB patients, 2018		Number	(%)
Patients with known HIV status who are HIV-positive		1 124	7%
- on antiretroviral therapy		909	81%

Drug-resistant TB care, 2018	
% of bacteriologically confirmed TB cases tested for rifampicin resistance <sup>ooo</sup>	
- New cases	
- Previously treated cases	
Laboratory-confirmed cases*	MDR/RR-TB: 433, XDR-TB: 8
Patients started on treatment**	MDR/RR-TB: 401, XDR-TB: 8
MDR/RR-TB cases tested for resistance to second-line drugs	252

Treatment success rate and cohort size	Success	Cohort
New cases registered in 2017	68%	26 954
Previously treated cases registered in 2017	56%	983
HIV-positive TB cases registered in 2017	66%	835
MDR/RR-TB cases started on second-line treatment in 2016	75%	236
XDR-TB cases started on second-line treatment in 2016	63%	8

TB preventive treatment, 2018	
% of HIV-positive people (newly enrolled in care) on preventive treatment	21%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	27% (25–30)

TB financing, 2019	
National TB budget (US\$ millions)	36
Funding source: 52% domestic, 25% international, 24% unfunded	

<sup>o</sup> Ranges represent uncertainty intervals

<sup>oo</sup> MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


<sup>ooo</sup> Calculated for pulmonary cases only

\* Includes cases with unknown previous TB treatment history

\*\* Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




Legend:  
■ Total TB incidence  
■ New and relapse TB cases notified  
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:  
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:  
■ Females ■ Males  Incidence

Treatment success rate (%)



Legend:  
■ New cases  
■ Previously treated cases  
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



Legend:  
■ Unfunded  
■ Funded internationally  
■ Funded domestically